Please login to the form below

Not currently logged in
Email:
Password:

cholera

This page shows the latest cholera news and features for those working in and with pharma, biotech and healthcare.

The power of pharma businesses to drive social change

The power of pharma businesses to drive social change

Our research teams are collaborating with peers from organisations around the world to help in the development of effective treatments for diseases such as Chagas, cholera, dengue fever and schistosomiasis.

Latest news

  • FDA approves first cholera vaccine in US FDA approves first cholera vaccine in US

    FDA approves first cholera vaccine in US. PaxVax’ s oral vaccine Vaxchora will be launched by September. ... It is a live attenuated vaccine, incorporating a weakened strain of the Vibrio cholera bacteria that causes the disease.

  • Sanofi enters vaccines partnership with Sutro Sanofi enters vaccines partnership with Sutro

    Sanofi Pasteur's vaccines currently cover 20 infectious diseases, including tuberculosis, cholera, influenza and hepatitis, and it is currently investigating a product to protect against the dengue virus.

  • Moving with the times: pharma market research and digital Moving with the times: pharma market research and digital

    Big data is already being harnessed to track disease. “ By following Twitter conversations alone, it was possible to predict a cholera epidemic two weeks before it would have shown up normally.

  • J&J to buy remaining shares in Crucell

    as hepatitis, influenza, typhoid and cholera.

  • Kicking the habit

    Preliminary data from a phase I trial of the vaccine, which comprises a nicotine derivative conjugated to a recombinant cholera toxin B, indicated that self-reported quit rates were considerably greater

More from news
Approximately 1 fully matching, plus 9 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Porterhouse Medical Group

Porterhouse Medical provides medical and scientific communication services to the pharmaceutical industry across the globe, with a focus on solutions...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics